From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL
Pharmacy Times
AUGUST 13, 2025
The development of grade 2 or higher peripheral neuropathy has been shown to increase with cumulative treatment, thus necessitating close monitoring and possibly altering the dosage. 2 Len, an immunomodulatory drug, contributes to the myelosuppression that characterizes the treatment regimen. link] Crump M, Neelapu SS, Farooq U, et al.
Let's personalize your content